RxDoctor Payments Data

Rupinder Brar, MD

Cardiovascular Disease · Yuba City, CANPI 1801862289

Payments from drug & device makers

$2,239in general payments, 2019–2025

Across 124 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$692
  • Johnson & Johnson$257
  • Novartis$164
  • E.r. Squibb & Sons, L.L.C.$156
  • Amarin Pharma, Inc.$128
  • Sanofi-aventis U.S. LLC$126
  • plus $717 from 14 others

What the payments were for

  • Food & beverage$2,10394%
  • Education$1366%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,239 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$848,519
Medicare patients
1,925
Services billed
8,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban744$822,331
EntrestoSacubitril/Valsartan172$228,082
XareltoRivaroxaban198$225,700
JardianceEmpagliflozin119$137,035
OzempicSemaglutide58$59,443
MultaqDronedarone Hcl24$40,953
Repatha SureclickEvolocumab44$37,525
Bumetanide494$15,168
FarxigaDapagliflozin Propanediol15$14,867
Praluent PenAlirocumab24$14,857
Ranolazine ErRanolazine122$9,854
VascepaIcosapent Ethyl11$9,075
Atorvastatin Calcium1,180$8,923
Losartan Potassium863$6,828
Terazosin Hcl386$6,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$164$228,082172 claims
Johnson & JohnsonXarelto$257$225,700198 claims
Boehringer IngelheimJardiance, Pradaxa$74$139,568132 claims
Sanofi-aventis U.S. LLCMultaq$126$40,95324 claims
AstraZenecaFarxiga$81$14,86715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Yuba City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →